ArticleVirchows Archiv : an international journal of pathology2026
The clinicopathologic characteristics and outcomes of uncommon KRAS mutations in patients with non-small cell lung cancer.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations occur in 25-30% of non-small cell lung cancer (NSCLC) patients. Pooled analyses in previous research have largely focused on the prognostic and predictive value of overall or common KRAS mutation status. Uncommon KRAS variants regarding their clinicopathologic features and associations with clinical outcomes following treatment are largely unexplored. This study characterizes the clinicopathologic features and outcomes associated with uncommon KRAS mutations in NSCLC. Of 4661 NSCLC patients subjected to oncogenic mutation profiling, 378 (8.1%) harbored KRAS mutations. Among the 209 cases with confirmed specific KRAS subtypes, 14 (6.7%, 14/209) presented with uncommon KRAS mutations. G12F was the most prevalent subtype, identified in 4 cases (28.6%, 4/14), followed by G12S and G12R, each detected in 2 cases (14.3%, respectively). Concomitant mutations were observed in 4 additional cases (28.6%), including G12D&G12V, G12A&G13R, G12V&G12C, and G12R&G12C. G12Y and G13R were each identified in 1 case (7.1% each). Compared with a matched cohort of patients with common KRAS mutations, no significant differences were observed in age, sex, smoking history, clinical stage, TTF-1 expression, or pathological subtypes. The uncommon KRAS mutation group had numerically inferior progression-free survival (PFS) and overall survival (OS); however, this difference did not reach statistical significance in our study (mean PFS: 15.14 months vs. 30.39 months, p = 0.074; mean OS: 24.50 months vs. 38.79 months, p = 0.157). These findings underscore the value of broad molecular profiling in establishing critical links between specific morphologic features, genetic alterations, and clinical behavior for tumors harboring these uncommon KRAS variants.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.